Literature DB >> 22421950

Local inhibition of angiogenesis by halofuginone coated silicone materials.

Martin C Jordan1, Philip H Zeplin.   

Abstract

Anti-angiogenic therapy is a promising approach for the treatment of increased angiogenesis in certain diseases. We aimed to investigate the local anti-angiogenic effect of silicone implants coated with Halofuginone, an angiogenesis inhibitor that inhibits synthesis of collagen-type-I and matrix metalloproteinases. The degree of angiogenesis was observed after implantation of surface modified Halofuginone eluting silicone implants into a submuscular pocket in rats over a period of 3 months. Subsequently, key mediators of angiogenesis (TGF-beta-1, bFGF, COL1A1, MMP-2, MMP-9, VEGF and PDGF) were established by immunohistological staining and RT-PCR and statistically evaluated. In comparison to uncoated silicone implants, Halofuginone eluting silicone implants lead to a significant local decrease of angiogenesis. Halofuginone eluting hybrid surface silicone implants have a significant local anti-angiogenic effect by down-regulating the expression activity of key mediators of angiogenesis.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22421950     DOI： 10.1007/s10856-012-4599-1

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN： 0957-4530            Impact factor:   3.896


  49 in total

1.  Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism.

Authors:  Karen O Yee; Caitlin M Connolly; Mark Pines; Jack Lawler
Journal:  Cancer Biol Ther       Date:  2006-02-19       Impact factor: 4.742

2.  MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes.

Authors:  T H Vu; J M Shipley; G Bergers; J E Berger; J A Helms; D Hanahan; S D Shapiro; R M Senior; Z Werb
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

3.  Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.

Authors:  Yuval Sheffer; Oded Leon; Jehonathan H Pinthus; Arnon Nagler; Yoram Mor; Olga Genin; Maya Iluz; Norifumi Kawada; Katsutoshi Yoshizato; Mark Pines
Journal:  Mol Cancer Ther       Date:  2007-01-31       Impact factor: 6.261

4.  Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.

Authors:  M Pines; A Domb; M Ohana; J Inbar; O Genina; R Alexiev; A Nagler
Journal:  Biochem Pharmacol       Date:  2001-11-01       Impact factor: 5.858

5.  Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.

Authors:  Henry B Koon; Barbara Fingleton; Jeannette Y Lee; Julia T Geyer; Ethel Cesarman; Robert A Parise; Merrill J Egorin; Bruce J Dezube; David Aboulafia; Susan E Krown
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

Review 6.  Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.

Authors:  Mark Pines; David Snyder; Shai Yarkoni; Arnon Nagler
Journal:  Biol Blood Marrow Transplant       Date:  2003-07       Impact factor: 5.742

7.  Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.

Authors:  David J Gross; Israel Reibstein; Lola Weiss; Shimon Slavin; Hagit Dafni; Michal Neeman; Mark Pines; Arnon Nagler
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

8.  Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.

Authors:  Uta B Hofmann; Andreas A O Eggert; Katharina Blass; Eva-B Bröcker; Jürgen C Becker
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

9.  Halofuginone: an inhibitor of collagen type I synthesis.

Authors:  I Granot; O Halevy; S Hurwitz; M Pines
Journal:  Biochim Biophys Acta       Date:  1993-02-13

10.  Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer.

Authors:  F J G M Kubben; C F M Sier; W van Duijn; G Griffioen; R Hanemaaijer; C J H van de Velde; J H J M van Krieken; C B H W Lamers; H W Verspaget
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640
View more
  4 in total

1.  Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft model.

Authors:  Faezeh Koohestani; Wenan Qiang; Amy L MacNeill; Stacy A Druschitz; Vanida A Serna; Malavika Adur; Takeshi Kurita; Romana A Nowak
Journal:  Hum Reprod       Date:  2016-04-29       Impact factor: 6.918

2.  Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.

Authors:  Patricia A Assis; Lorena L De Figueiredo-Pontes; Ana Silvia G Lima; Vitor Leão; Larissa A Cândido; Carolina T Pintão; Aglair B Garcia; Fabiano P Saggioro; Rodrigo A Panepucci; Fernando Chahud; Arnon Nagler; Roberto P Falcão; Eduardo M Rego
Journal:  J Exp Clin Cancer Res       Date:  2015-06-23

Review 3.  Antiangiogenic Effect of Alkaloids.

Authors:  Masoud Alasvand; Vahideh Assadollahi; Roberto Ambra; Ehsan Hedayati; Wesam Kooti; Ilaria Peluso
Journal:  Oxid Med Cell Longev       Date:  2019-04-21       Impact factor: 6.543

4.  Inhibition of TGF-β signaling with halofuginone can enhance the antitumor effect of irradiation in Lewis lung cancer.

Authors:  Runlong Lin; Shuai Yi; Linlin Gong; Weishuai Liu; Peng Wang; Ningbo Liu; Lujun Zhao; Ping Wang
Journal:  Onco Targets Ther       Date:  2015-12-02       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.